Conference Coverage: EHA 2024 – Focus on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia

June 15, 2024

Faculty Chair

Elias Jabbour, MD

MD Anderson Cancer Center, Houston, TX, USA

Faculty Members

Daniel Pollyea, MD, MS
University of Colorado School of Medicine, Aurora, CO, USA

Courtney DiNardo, MD
MD Anderson Cancer Center, Houston, TX, USA

Uma Borate, MD, MBBS
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

Tapan Kadia, MD
MD Anderson Cancer Center, Houston, TX, USA

Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA

Eytan Stein, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Alexander E. Perl, MD
Abramson Cancer Center, Penn Medicine, Philadelphia, PA, USA

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Advances in AML: Newly Diagnosed
  • Advances in AML: R/R Disease – Monotherapies
  • Advances in AML: R/R Disease – Combination Therapies
  • New Developments in First-Line Treatment of MDS
  • New Developments in Treatment of R/R MDS

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.